Every day 1000 children die from a disease that no one talks about
Sickle cell disease is the world's most common genetic disorder, affecting over 12 million people, the disease kills half of children with the severe form before age five, predominantly impacting black populations.
Despite its high mortality, sickle cell remains largely underfunded and overlooked globally, with limited access to life-saving treatments.
This silent epidemic claims more lives than HIV/AIDS in Africa...
Donate Now
Auction & Lottery Catalog
The International Sickle Cell Fund extends its heartfelt thanks to Cathy Guetta whose unwavering dedication as a Global Ambassador for Sickle Cell Disease has made this partnership with Fast Lane Drive possible
Sickle cell is #1 genetic disease in the World
Sickle cell disease is a genetic disorder affecting hemoglobin, the substance in red blood cells that carries oxygen. In affected individuals, red blood cells are fragile, destroyed quickly, and deformed into a sickle shape, obstructing blood flow and causing oxygen deprivation to organs.
This results in anemia, pain crises, and a higher risk of infections. Vaso-occlusive crises, marked by severe and unpredictable pain, can affect bones and organs.
In Africa, high infant mortality rates are due to limited access to treatment, exacerbating the disease's devastating impact. Despite its scale and devastating consequences, this disease remains largely overlooked.
- 80% of patients are in Africa.
- 50% of affected children die before the age of 5.
- < 20% of patients have access to hydroxyurea treatment
We created ISC Fund to give access to the sickle cell treatment in Africa
The first treatment for Sickle Cell disease produced in Africa at cost
The International Sickle Cell Fund financially supports the NGO Drep Afrique, particularly the DREPAF® project.
The association has signed a unique humanitarian agreement with the laboratory Teranga Pharma to produce and distribute the only treatment that significantly reduces infant mortality among patients with Sickle Cell Disease using the hydroxyurea molecule.
DREPAF® is produced in Senegal by Teranga Pharma. The first treatment sold at cost, available in 2025 in all pharmacies from $60 per year.
The program will soon be available in four other African countries.
The first treatment for Sickle Cells disease produced in Africa at cost
The International Sickle Cell Fund financially supports the NGO Drep Afrique, particularly the DREPAF® project.
The association has signed a unique humanitarian agreement with the laboratory Teranga Pharma to produce and distribute the only treatment that significantly reduces infant mortality among patients with Sickle Cell Disease using the hydroxyurea molecule.
DREPAF® is produced in Senegal by Teranga Pharma. The first treatment sold at cost, available in 2025 in all pharmacies from $60 per year.
The program will soon be available in four other African countries.
You can save a life for $60
The generic hydroxyurea formulation DREPAF® is sold at cost price in Senegal, making it three times cheaper than the few treatments available today.
However, even at this reduced price, the poorest families with multiple children affected by the disease cannot afford the treatment.
This is why the International Sickle Cell Fund is reaching out to your generosity to help save thousands of children suffering from the severe form of the disease.
Together, we can change their lives!
Donate NowYou can save a life for $60
The generic hydroxyurea formulation DREPAF® is sold at cost price in Senegal, making it three times cheaper than the few treatments available today.
However, even at this reduced price, the poorest families with multiple children affected by the disease cannot afford the treatment.
This is why the International Sickle Cell Fund is reaching out to your generosity to help save thousands of children suffering from the severe form of the disease.
Together, we can change their lives!
Donate Now
We invite you to visit Drep Africa for detailed information about the NGO and its missions supported by the ISC Fund.
For any inquiries, please feel free to contact Emmanuel Jayr, Co-founder and Treasurer of the ISC Fund, at manujayr@gmail.com.
© 2025 ISC Fund. All rights reserved